Bucci L, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-u...
targeting of malignant B cells by CAR T cells has significantly improved the treatment of hematologic neoplasms. Aside from malignant B cells, autoreactive B cells can also cause severe pathologic effects in the form of autoimmune diseases. Disorders such as systemic ...
近日,国际顶级期刊NEJM(The New England Journal of Medicine)发表了一篇题为“CD19 CAR T-Cell Therapy in Autoimmune Disease-A Case Series with Follow-up.”的文章。来自德国埃尔兰根大学医院研究人员使用 CAR-T细胞疗法治疗15名患有严重...
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N Engl J Med. 2024 Feb 22;390(8):687-700. 关于BioBro大师兄 BioBro大师兄是一个聚焦生物医药领域产学研的共享平台,包括专业交流以及干货内容和供应链信息分享,持续关注细胞治疗、基因治疗、干细胞药物、抗体药物等领域的前...
自2022年Carl June在Cell上发表题为"CAR T therapy extends its reach to autoimmune diseases"的论文起,CD19 CAR-T细胞拦截B细胞驱动的自身免疫性疾病的概念正在逐渐得到验证。 其中一方面,单纯通过靶向CD20造成异常的B细胞耗竭可能还不够,因为B细胞前体(在SSc等适应症中特异性扩增)和可能负责自身抗体产生的浆母细胞...
总的来说,CAR-T细胞疗法在风湿性自身免疫性疾病患者中的安全性和有效性不受影响,此外还对风湿病取得了更好的生化控制。 参考文献 Wang JS,et al. CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurr...
[5] OP0279 CAR-T CELL TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS- SAFETY AND PRELIMINARY EFFICACY DATA FROM THE FIRST FOUR PATIENTS https://ard.bmj.com/content/81/Suppl_1/185.1.abstract [6]CAR T therapy extends its reach to autoimmune diseases ...
CONCLUSIONS In this case series, CD19 CAR T-cell transfer appeared to be feasible, safe, and efficacious in three different autoimmune diseases, providing rationale for further controlled clinical trials. (Funded by Deutsche Forschungsgemeinschaft and others.). ---分割线--- 点击链接:https://www...
However, CD19 CAR T cells also target autoreactive B cells that trigger autoimmune diseases (AID) including systemic lupus erythematosus (SLE), idiopahtic inflammatory myositis (IIM) and systemic sclerosis (SSc). Achieving long-term remission in AID with standard therapy remains challenging and ...
Wei Zhang et al.BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy. hLife, 2024, doi:10.1016/j.hlife.2024.05.005. CIDP study explores dual-target CAR-T cell therapy for the treatment of relapsed/refractory autoimmune disorders. https://medicalxpress...